MoonLake Immunotherapeutics (MLTX)
NEUTRAL基本面
34
价格
$15.57
市值
$1.31B
第一部分 · 这家公司值多少
概览
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
0
截至2025/12/31的财政年度
净利润
$-227M
截至2025/12/31的财政年度
自由现金流
$-196M
股东权益合计
$304M
负债合计
$120M
流动比率
12.56
利息覆盖率
26.58
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$28.54
当前价格
$15.57
安全边际
+45.4%
公允价值区间
$27.11 - $29.97
估算方法
估值指标
市盈率（P/E）
-
ROE
-74.7%
市净率（P/B）
3.05
P/FCF
-
毛利率
-
ROIC
-40.1%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-40.1%
WACC
10.0%
ROIC − WACC
-50.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过（7）
- Price CAGR 5.59%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 77% Buy
- Share Dilution 2.3%
未通过（9）
- EPS shows upward trend
- ROIC -40.1%
- P/B Ratio 3.05
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -85.6%
- Earnings Surprise avg -9.9%
- Piotroski F-Score 1/9
不可用（11）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 48 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 37 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | - |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | - |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | - |
| Joana Cortez | Associate Vice-President of Legal & Compliance | - |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | - |
| Luciana Marques | Associate Vice-President of HR, People and Culture | - |
| Ms. Nuala Brennan | Chief Clinical Development Officer | - |
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for MLTX, sourced from Markets Gazette.
- 3/30/2026POSITIVEMoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.
via Markets Gazette